Premium
P2‐277: CAREGIVER PREFERENCE AND TREATMENT OUTCOMES IN PATIENTS WITH MILD‐TO‐MODERATE ALZHEIMER'S DISEASE TREATED WITH ORAL OR TRANSDERMAL MONOTHERAPY: ANALYSIS OF PROSPECTIVE DATA FROM THE RECAP STUDY
Author(s) -
Amin Aref Hany Mohamed,
Bassil Nazem,
Kandiah Nagaendran,
Pai MingChyi,
Lee JaeHong,
Srinivasan A.V.,
di Tommaso Shelley,
Yuksel Ozgur
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.955
Subject(s) - medicine , rivastigmine , tolerability , adverse effect , transdermal , concomitant , transdermal patch , donepezil , observational study , prospective cohort study , dementia , disease , pharmacology
Figure 1. Perc end of study (W ness Set) Note: Effectiv during the stud effectiveness a consists of 89. zPatients in the ment were not test statistic to *A p-value <0 tions between OUTCOMES IN PATIENTS WITH MILD-TOMODERATE ALZHEIMER’S DISEASE TREATED WITH ORAL OR TRANSDERMAL MONOTHERAPY: ANALYSIS OF PROSPECTIVE DATA FROM THE RECAP STUDY Hany Mohamed Amin Aref, Nazem Bassil, Nagaendran Kandiah, Ming-Chyi Pai, Jae-Hong Lee, A.V. Srinivasan, Shelley di Tommaso, Ozgur Yuksel, Ain Shams University, Cairo, Egypt; Saint Georges Hospital, Beirut, Lebanon; National Neuroscience Institute, Tan Tock Seng Hospital, Singapore, Singapore; National Cheng Kung University Hospital, Tainan, Taiwan; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India; Novartis Pharma AG, Basel, Switzerland. Contact e-mail: nagaendran_kandiah@nni.com.sg